selected scholarly activity
-
conferences
- Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.. Respirology. 635-644. 2022
- Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest. 1594-1597. 2022
- Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest. 1320-1329. 2022
- Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulmonary Medicine. 223. 2019
- The prevalence of bronchitis and associations with spirometry in patients with interstitial lungdisease in a Canadian tertiary care centre. European Respiratory Journal. 2019
- Assessing the Role of ATF6α in the Alternative Activation of Macrophages in the Progression of Fibrotic Lung Diseases. American Journal of Respiratory and Critical Care Medicine. 2019
- Dectin-1 Is a Marker of Alternatively Activated Macrophages and a Therapeutic Target in Interstitial Fibrotic Lung Diseases. American Journal of Respiratory and Critical Care Medicine. 2019
- Investigating the Expression of CCL18 in Alternatively Activated Macrophages and in the Progression of Different Fibrotic Lung Diseases. American Journal of Respiratory and Critical Care Medicine. 2019
- The IRE/XBP1 Pathway Is Activated in Alternatively Activated Macrophages in Interstitial Fibrotic Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2019
- FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-RELATED PULMONARY FIBROSIS. Rheumatology. 2019
- Disparities in the Treatment of Patients with Interstitial Lung Disease in Canada. American Journal of Respiratory and Critical Care Medicine. 2019
- Minimally Important Difference (MID) for the European Quality of Life 5 Dimensions (EQ-5D) in Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2019
- Oxygen Desaturation in Six Minute Walk Test Compared to Cardiopulmonary Exercise Testing in Interstitial Lung Disease: A Pilot Study. American Journal of Respiratory and Critical Care Medicine. 2019
- Workplace Productivity in Patients with Connective Tissue Disease Associated Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2018
- Workplace Productivity in Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2018
- Antiphospholipid antibody syndrome: diffuse alveolar hemorrhage and Libman-Sacks endocarditis in the absence of prior thrombotic events.. Ulster Medical Journal. 47-49. 2014
- Profound Exertional Hypoxia In A Diabetic Patient With Subpleural Interstitial Markings. American Journal of Respiratory and Critical Care Medicine. 2014
-
journal articles
- Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis.. The Lancet Respiratory Medicine. 12:848-851. 2024
- Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response. Rheumatology. 63:2734-2740. 2024
- BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung Disease.. Chest. S0012-3692(24)04930-4. 2024
- Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort. Respirology. 29:596-604. 2024
- The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung Disease. Chest. 166:517-527. 2024
- Characteristics and risk factors of interstitial pneumonia with autoimmune features. Respiratory Medicine. 221:107500-107500. 2024
- Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest. 164:1466-1475. 2023
- Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 20:1726-1734. 2023
- Association Between the Pulmonary Artery Pulsatility Index and Prognosis in Pulmonary Arterial Hypertension: A Multicentre Study. CJC OPEN. 5:545-553. 2023
-
Myeloid‐specific deletion of activating transcription factor 6 alpha increases
CD11b + macrophage subpopulations and aggravates lung fibrosis. Immunology and Cell Biology. 101:412-427. 2023 - Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis. European Respiratory Journal. 61:2300208-2300208. 2023
- Pulmonary hypertension and associated outcomes in noncardiac surgery: A systematic review and meta-analysis. Heart and Lung: Journal of Acute and Critical Care. 58:21-27. 2023
- Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. Chest. 163:345-357. 2023
- Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions. American Journal of Respiratory and Critical Care Medicine. 207:102-105. 2023
- Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis. European Respiratory Journal. 61:2202261-2202261. 2023
- Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respiratory Research. 23:54. 2022
- Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease. Respirology. 27:854-862. 2022
- Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal. 60:2102571-2102571. 2022
- Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax. 77:589-595. 2022
- Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 19:863-867. 2022
- Heterogeneous manifestation of pulmonary ossification in idiopathic pulmonary fibrosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 6:121-125. 2022
- Novel folliculin gene mutation and an elevated serum vascular endothelial growth factor-D level in the context of cystic lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 6:58-62. 2022
- Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine. 191:106722-106722. 2022
- Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 19:20-27. 2022
- Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research. 22:202. 2021
- Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Viruses. 13:2239-2239. 2021
- Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society. 18:1661-1668. 2021
- Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. Respirology. 26:683-689. 2021
- FK506-Binding Protein 13 Expression Is Upregulated in Interstitial Lung Disease and Correlated with Clinical Severity. A Potentially Protective Role. American Journal of Respiratory Cell and Molecular Biology. 64:235-246. 2021
- Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 76:37-43. 2021
- A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research. 21:322. 2020
- Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest. 158:2270-2274. 2020
- Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 4:214-225. 2020
- Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease–associated Interstitial Lung Disease. Annals of the American Thoracic Society. 17:1077-1084. 2020
- Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest. 158:1069-1078. 2020
- Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough. Respiratory Medicine. 170:106067-106067. 2020
- Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. International Journal of Cardiology. 306:181-186. 2020
- A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator. Journal of Thoracic Disease. 11:5547-5556. 2019
- Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest. 156:887-895. 2019
- Update in the diagnostic approach to fibrotic interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 3:155-159. 2019
- Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. European Respiratory Journal. 52:1701857-1701857. 2018
- Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. The Lancet Respiratory Medicine. 5:591-598. 2017
- Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. European Respiratory Journal. 49:1700811-1700811. 2017
- Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?. American Journal of Respiratory and Critical Care Medicine. 194:1315-1317. 2016
- High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society. 13:1640-1647. 2016
- Pulmonary hypertension: diagnostic approach and optimal management. CANADIAN MEDICAL ASSOCIATION JOURNAL. 188:804-812. 2016
- Riociguat for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine. 9:679-695. 2015
- The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry.. Canadian Respiratory Journal. 17206. 2015
- Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. Respirology. 20:1010-1022. 2015
- Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine. 20:87-94. 2014